Secondaries announced 1.04.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Akebia Therapeutics, Inc.
Symbol: AKBA
Price: Last trade $12.56
Trade Date: 1/7
Shares: 6 million
Underwriter(s) Morgan Stanley, UBS Investment Bank, JMP Securities
Co Manager(s) Needham & Co., Brean Capital
Rating=Subscription Needed

Company: Acceleron Pharma Inc.
Symbol: XLRN
Price: Last trade $44.86
Trade Date: 1/6
Shares: 3.3 million
Underwriter(s) Morgan Stanley, Leerink Partners LLC, UBS Investment Bank, JMP Securities
Rating=Subscription Needed